August 24, 2026

Can Ozempic Treat Addiction? What the Research Actually Shows

Emerging treatment · What the evidence shows

People taking Ozempic for diabetes keep reporting the same strange thing: alcohol lost its pull, and they never set out to quit. Researchers are now taking that seriously. Here is what the science actually supports — and what it does not, yet.

600,000people in the largest study to date, published in The BMJ
2028when the VA’s phase 3 alcohol trial reaches primary completion
ZeroGLP-1 medications currently FDA-approved to treat addiction

A veteran who had tried to quit smoking for a decade started a GLP-1 drug for his diabetes and simply lost interest in cigarettes. No patch. No quit date. Another patient, prescribed one for weight loss, found that alcohol had stopped mattering after years of failed attempts to stop drinking.

Neither of them started the medication to quit anything.

Stories like these have been accumulating in clinics, on social media, and around kitchen tables for a few years now, across substances as different as opioids, nicotine, alcohol and gambling. Clinicians have described the pattern as having no real precedent in medicine. That is a strong claim, and it is worth examining carefully rather than getting swept up in.

What the research actually found

2025 — the first controlled signal

A phase 2 trial published in JAMA Psychiatry found that low-dose weekly semaglutide reduced both craving and laboratory alcohol self-administration in adults with alcohol use disorder. The authors concluded the result justified larger trials — deliberately measured language.

March 2026 — the large cohort study

Researchers at Washington University in St. Louis published work in The BMJ examining roughly 600,000 US veterans with type 2 diabetes. GLP-1 medications were associated with reduced risk of substance use disorders across every major substance studied — suggesting the drugs act on a shared biological pathway rather than on any one drug.

2026 — randomised evidence arrives

A randomised, double-blind, placebo-controlled trial published in The Lancet tested once-weekly semaglutide in patients with alcohol use disorder and co-occurring obesity. A separate phase 2 trial of an oral formulation at the University of Colorado has now completed. Another trial found dulaglutide reduced drinking.

Now — the definitive trials are running

The Department of Veterans Affairs has launched a phase 3 trial of semaglutide in veterans with moderate to severe alcohol use disorder. Primary completion is estimated for 2028. More than a dozen further trials are underway or enrolling.

Why it might work at all

GLP-1 receptors are not confined to the pancreas and gut. They appear throughout the brain’s reward circuitry — including the nucleus accumbens and ventral tegmental area, the same regions where dopamine drives wanting.

The working theory is that these medications dampen dopamine signalling in that circuit, blunting the reward value of whatever the brain has learned to chase. Which would explain the oddest feature of the reports: people do not describe fighting a craving and winning. They describe the craving quietly failing to show up.

If that holds, it is genuinely significant. Every medication we currently use for addiction is substance-specific — one for opioids, another for alcohol, another for nicotine. A drug acting on a shared vulnerability underneath all of them would be a different kind of tool entirely.

What this does not mean — yet

This is the part you will not find on treatment centre websites promising a breakthrough. It matters more than the promising part.

1
No GLP-1 is FDA-approved for addiction. Every use for cravings is off-label. That is not a technicality — it governs what a physician can prescribe and what insurance will pay for.
2
Much of the strongest data is observational. The BMJ cohort studied people already taking these drugs for diabetes. Association is not causation, and people prescribed GLP-1s differ from those who are not in ways statistics can only partly correct for.
3
Alcohol has far more evidence than opioids. Most completed trials studied alcohol use disorder. Opioid data is thinner and still being actively studied.
4
It cannot manage withdrawal. Nothing about a GLP-1 makes alcohol or benzodiazepine withdrawal safe. Those withdrawals can cause seizures and can be fatal, and they still require medical supervision.
5
Reduced craving is not recovery. Addiction is built on top of trauma, pain, isolation and habit. A medication that quiets the wanting creates room to do that work. It does not do the work.

Do not source these medications outside a physician’s care. Compounded and grey-market GLP-1 products are widely sold online and carry real risks of contamination and dosing error. If you want to explore this, it is a conversation with a doctor who knows your full history.

What works right now, while the trials run

The honest headline is that 2028 is a long way off if you are struggling this month. There are medications with established evidence available today, and they remain badly underused.

Medication-assisted treatment

MAT is the standard of care for opioid and alcohol use disorder, and the evidence for it is not preliminary. Options at Mountain’s Edge include Vivitrol and Sublocade.

Medically supervised detox

Withdrawal managed by physicians and nurses with 24-hour monitoring — the part no emerging medication replaces.

Co-occurring mental health care

Depression, anxiety, PTSD and trauma travel with addiction. Treating one without the other is how people end up back where they started.

Structure and time

Unglamorous and still the most reliable ingredient we have. Weeks in a place organised around recovery, with people who know your name.

How we approach it at Mountain’s Edge

A growing number of people arriving for treatment are already taking a GLP-1 medication prescribed by their own doctor. Our clinical team reviews every medication you are on as part of intake, coordinates with your prescribing physician where appropriate, and factors it into your care plan rather than ignoring it.

What we will not do is market an unapproved treatment as a breakthrough to get you through the door. When the phase 3 data lands, we will read it and act on it. Until then we will tell you plainly what is established and what is still a hypothesis.

Mountain’s Edge is a Joint Commission–accredited facility in Union Dale, Pennsylvania, about 30 minutes north of Scranton. We accept Pennsylvania Medicaid and most major commercial insurance.

Programs

Common questions

Can I get Ozempic prescribed for alcohol cravings?

Not as an approved indication. No GLP-1 medication is FDA-approved to treat addiction, so any such use is off-label and at a physician’s discretion. Insurance coverage for off-label use is inconsistent.

I’m already on a GLP-1. Should I stop before treatment?

Do not stop any prescribed medication without speaking to the doctor who prescribed it. Bring it up at intake — our clinical team reviews everything you are taking and coordinates care accordingly.

Would a GLP-1 mean I could skip rehab?

No. Even in the most favourable trials these drugs reduce craving; they do not manage withdrawal, treat co-occurring conditions, or address what drove the use. And withdrawal from alcohol or benzodiazepines still requires medical supervision.

Does it work for opioids too?

The evidence is much thinner than for alcohol. Early observational data suggests a possible association with fewer overdoses, but this is still being actively studied. For opioid use disorder, established MAT options have far stronger evidence today.

When will we know for certain?

The VA’s phase 3 trial in veterans with alcohol use disorder has a primary completion estimate of 2028. More than a dozen other trials are underway, so partial answers will arrive sooner.

Sources

You don’t have to wait for 2028

If drinking or using is a problem in your life right now, there is treatment with established evidence available today. Call and we will talk through what fits your situation and what your insurance covers — including how any medication you are already on fits into it.

If you or someone you love is in immediate danger, call 911. For free, confidential help finding treatment anywhere in Pennsylvania, call PA Get Help Now at 1-800-662-HELP (4357), available 24/7. This article is for general information and is not medical advice. Do not start or stop any medication without speaking to your physician.

Leave A Comment